CA2556489C - Utilisation de folates pour la prevention et le traitement de maladies vasculaires - Google Patents

Utilisation de folates pour la prevention et le traitement de maladies vasculaires Download PDF

Info

Publication number
CA2556489C
CA2556489C CA2556489A CA2556489A CA2556489C CA 2556489 C CA2556489 C CA 2556489C CA 2556489 A CA2556489 A CA 2556489A CA 2556489 A CA2556489 A CA 2556489A CA 2556489 C CA2556489 C CA 2556489C
Authority
CA
Canada
Prior art keywords
acid
folate
pharmaceutically acceptable
mthf
tetrahydrofolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2556489A
Other languages
English (en)
Other versions
CA2556489A1 (fr
Inventor
Charalambos Antoniades
Cheerag Shirodaria
Keith M. Channon
Rudolf Moser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck et Cie
Original Assignee
Merck Eprova AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Eprova AG filed Critical Merck Eprova AG
Priority to CA2556489A priority Critical patent/CA2556489C/fr
Publication of CA2556489A1 publication Critical patent/CA2556489A1/fr
Application granted granted Critical
Publication of CA2556489C publication Critical patent/CA2556489C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur l'utilisation de folates pour prévenir et/ou traiter des maladies cardiovasculaires, comme l'athérosclérose, et, en particulier, pour réguler l'oxyde nitrique synthétase endothéliale. L'invention concerne également des préparations pharmaceutiques composées desdits folates et un vecteur pharmaceutiquement acceptable, facultativement en combinaison avec d'autres agents pharmaceutiquement actifs, de même que des méthodes therapeutiques faisant appel à ces folates ou à des préparations pharmaceutiques de ceux-ci.
CA2556489A 2006-08-21 2006-08-21 Utilisation de folates pour la prevention et le traitement de maladies vasculaires Active CA2556489C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2556489A CA2556489C (fr) 2006-08-21 2006-08-21 Utilisation de folates pour la prevention et le traitement de maladies vasculaires

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2556489A CA2556489C (fr) 2006-08-21 2006-08-21 Utilisation de folates pour la prevention et le traitement de maladies vasculaires

Publications (2)

Publication Number Publication Date
CA2556489A1 CA2556489A1 (fr) 2008-02-21
CA2556489C true CA2556489C (fr) 2011-06-14

Family

ID=39103078

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2556489A Active CA2556489C (fr) 2006-08-21 2006-08-21 Utilisation de folates pour la prevention et le traitement de maladies vasculaires

Country Status (1)

Country Link
CA (1) CA2556489C (fr)

Also Published As

Publication number Publication date
CA2556489A1 (fr) 2008-02-21

Similar Documents

Publication Publication Date Title
CA2477101C (fr) Utilisation de folates pour prevenir et traiter l'inflammation et les maladies associees aux inflammations
US6995158B2 (en) Pharmaceutical preparation containing at least folic acid or a folate and tetrahydrobiopterin (BH4) or derivatives thereof used for the treating or preventing cardiovascular or neurological disorders by modulation of the activity of nitric oxide synthase (NOS)
Heller et al. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin
Galley et al. The effects of intravenous antioxidants in patients with septic shock
Pietrzik et al. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics
Pinheiro et al. The potential of stimulating nitric oxide formation in the treatment of hypertension
US20100130453A1 (en) Use of folates for the prevention and treatment of vascular diseases
AU7007998A (en) The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for the influencing the homocysteine level, particularly for assisting the remethylation of homocysteine
Kelley Effects of drugs on uric acid in man
Pereira et al. Nitric oxide synthesis and biological functions of nitric oxide released from ruthenium compounds
Stanger et al. Enzymatic and non-enzymatic antioxidative effects of folic acid and its reduced derivates
do Vale et al. Nebivolol prevents ethanol-induced reactive oxygen species generation and lipoperoxidation in the rat kidney by regulating NADPH oxidase activation and expression
KR20070083734A (ko) 신장 질환 환자에서 영양 결핍의 보충을 위한 방법과조성물
JP2009514776A (ja) ５，１０−メチレンテトラヒドロホラートの安定な医薬調合物
CA2556489C (fr) Utilisation de folates pour la prevention et le traitement de maladies vasculaires
McCarty Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine–an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction
AU2006203758B2 (en) Use of folates for the prevention and treatment of vascular diseases
Miner et al. Pyridoxine improves endothelial function in cardiac transplant recipients
TWI359019B (en) Use of folates for the prevention and treatment of
KR20170015948A (ko) 혈관 질환의 예방 및 치료를 위한 폴레이트의 용도
KR20080015325A (ko) 혈관 질환의 예방 및 치료를 위한 폴레이트의 용도
KR20140081775A (ko) 혈관 질환의 예방 및 치료를 위한 폴레이트의 용도
PT103658A (pt) Utilização de folatos para a prevenção e o tratamento de doenças vasculares
KR20140107162A (ko) 혈관 질환의 예방 및 치료를 위한 폴레이트의 용도
US20240316050A1 (en) Treatment of disorders associated with low bh4 bioavailability

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250221